Contents: The HIV\/AIDS vaccine research effort: an update<\/strong> Top papers of 2002 – John G. Bartlett, M.D.<\/strong> Report from the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV<\/strong> December 2002 Vol. VII, No. 4<\/p>\n HIV superinfection and immune control: implications for vaccine development?<\/strong> Dendritic cells: immune activators of virus facilitators?<\/strong> Determinants of mucosal HIV replication and shedding<\/strong> http:\/\/www.prn.org\/prn_nb_cntnt\/current.htm<\/a><\/p>\n How club drugs make HIV more dangerous<\/strong> ICCAC Report: HIV grudgingly yields some secrets (or, orthography and the retrovirus)<\/strong> http:\/\/www.thebody.com\/tag\/tagix.html<\/a><\/p>\n SSITT downer? Nattering nabobs\u2019 noxious spin, and the imperiled future of STI research<\/strong><\/p>\n \u201cWhen an investigational drug causes a 0.4 log drop in viral load, it is evidence of biological activity. When the first large auto-vaccination study produces the same result, it signals the end of an entire field of HIV research.\u201d<\/p>\n Richard Jefferys analyses the results from the Swiss-Spanish Intermittent Treatment Trial (SSITT) more optimistically than the lead investigators and argues for continued research in this area. Research and policy recommendations for HIV\/HCV coinfection<\/strong> International AIDS Vaccine Initiative report now online:<\/p>\n A workshop in Seattle highlights the still-formidable barriers to clinical trials of vaccines in paediatric populations, which are at high risk of HIV infection via breastmilk in many areas of the world.<\/p>\n Difficulties faced by representatives of regulatory agencies and institutional review boards in approving trials and licensing HIV vaccines and microbicides.<\/p>\n A leader at one of Africa\u2019s premiere AIDS units and clinical research sites, Glenda Gray has been part of pioneering research, especially in the field of reducing mother-to-child transmission. Here, she discusses the team\u2019s recent expansion into vaccines and the challenges of involving young people in vaccine trials.<\/p>\n
\n http:\/\/hopkins-aids.edu\/publications\/report\/report_toc_03.html<\/a><\/p>\n
\nBy Chris Beyrer M.D., M.P.H.
\nhttp:\/\/hopkins-aids.edu\/publications\/report\/jan03_3.html<\/a><\/p>\n
\nAuthor\u2019s choice for the twelve most important HIV-related publications of 2002 that have direct clinical relevance:
\n http:\/\/hopkins-aids.edu\/publications\/report\/jan03_5.html<\/a><\/p>\n
\nBy Joseph Cofrancesco Jr., M.D., M.P.H.
\n http:\/\/hopkins-aids.edu\/publications\/report\/jan03_2.html<\/a><\/p>\nPRN Notebook \u2013 December 2002<\/h2>\n
\nTodd Allen, DVM, PhD<\/p>\n
\nMelissa Pope, PhD<\/p>\n
\nScott J. Brodie, DVM, PhD<\/p>\nIAPAC December 2002 Journal<\/h2>\n
\nJan Swanson and Alan Cooper
\nClub drugs, or recreational drugs, have recently been associated with increased high-risk sexual behaviors that, in turn, may cause higher incidence of HIV\/AIDS. And, there is increasing evidence that club drugs interact with highly active antiretroviral therapy. What role should physicians and allied healthcare professionals play?
\nhttp:\/\/www.thebody.com\/iapac\/dec02\/club_drug.html<\/a><\/p>\n
\nMark Mascolini
\nWhile many of HIV\u2019s dark mysteries remain tightly under wraps, the 42nd ICAAC yielded some clues to antiretroviral management. New studies focused on starting, stopping, and changing therapy – and on new antiretrovirals.
\nhttp:\/\/www.thebody.com\/iapac\/dec02\/icaac.html<\/a><\/p>\nTAGline \u2013 November 2002<\/h2>\n
\nhttp:\/\/www.thebody.com\/tag\/nov02\/altered_states.html<\/a><\/p>\n
\nCritical recommendations from updated coinfection report, Version 2.0, February 2003.
\n(pdf format only)
\nhttp:\/\/www.aidsinfonyc.org\/tag\/comp\/hcvResearch.pdf<\/a><\/p>\nIAVI Report – December 2002\/January 2003<\/h2>\n
\n
\n
\n